<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Triamcinolone (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Triamcinolone (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Triamcinolone (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12330" href="/d/html/12330.html" rel="external">see "Triamcinolone (topical): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16062" href="/d/html/16062.html" rel="external">see "Triamcinolone (topical): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9606513"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kenalog;</li>
<li>Kourzeq;</li>
<li>Oralone;</li>
<li>Sila III [DSC];</li>
<li>Trianex [DSC];</li>
<li>Triasil;</li>
<li>Triderm;</li>
<li>Tritocin [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870638"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aristocort C;</li>
<li>Aristocort R;</li>
<li>Oracort;</li>
<li>Triaderm</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9608405"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Topical</li></ul></div>
<div class="block doa drugH1Div" id="F9606707"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>The potency classifications of topical triamcinolone products are provided in the table. In general, start with the lowest-potency agent appropriate for the condition severity and application site. Vehicle, concentration, site of application, use of occlusive dressings, and other factors can alter potency. Optimal response depends on choosing a vehicle that is appropriate for body location, lesion characteristics, and patient preference.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Potency of Topical Triamcinolone Products<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Vehicle</p></th>
<th align="center">
<p style="text-indent:0em;">Strength</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Potency (According to the US Classification System)</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Goldstein 2019; Tadicherla 2009</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Cream, Ointment</p></td>
<td align="center">
<p style="text-indent:0em;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;">High (group 3)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Aerosol spray</p></td>
<td align="center">
<p style="text-indent:0em;">(delivering ~0.2 mg per 2-second spray)</p></td>
<td align="center">
<p style="text-indent:0em;">Medium (group 4)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cream, Ointment, Oral/Dental Paste</p></td>
<td align="center">
<p style="text-indent:0em;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;">Medium (group 4)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Ointment</p></td>
<td align="center">
<p style="text-indent:0em;">0.05%</p></td>
<td align="center">
<p style="text-indent:0em;">Medium (group 4)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Lotion</p></td>
<td align="center">
<p style="text-indent:0em;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;">Lower-mid (group 5)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Ointment</p></td>
<td align="center">
<p style="text-indent:0em;">0.025%</p></td>
<td align="center">
<p style="text-indent:0em;">Lower-mid (group 5)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Cream, Lotion</p></td>
<td align="center">
<p style="text-indent:0em;">0.025%</p></td>
<td align="center">
<p style="text-indent:0em;">Low (group 6)</p></td></tr></tbody></table>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32098c73-0aa0-4b71-baf6-b4df5928bd0d">Aphthous stomatitis, mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aphthous stomatitis (recurrent), mild to moderate: Note: </b>Initiate at first indication of an outbreak.</p>
<p style="text-indent:-2em;margin-left:4em;">Triamcinolone 0.1% (oral/dental paste): Topical: Apply a small amount to the lesion 2 to 4 times daily until healed; do not rinse afterwards and avoid eating or drinking for 30 minutes after application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25346356','lexi-content-ref-10905785','lexi-content-ref-25254615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25346356','lexi-content-ref-10905785','lexi-content-ref-25254615'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis (eczema): Note:</b> Concurrent use of emollients (applied liberally) is recommended. In the management of corticosteroid-responsive dermatoses, lower-potency agents are often preferred for sites at increased risk for corticosteroid-induced skin atrophy (eg, face, intertriginous areas). However, use of higher-potency agents in these areas can be appropriate for certain indications when prescribed under the guidance of a dermatologist. See "Note" at the top of the "Dosing: Adult" field for potency guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild disease:</b> Triamcinolone 0.025% (ointment, cream, lotion) or 0.1% (lotion): Topical: Apply once or twice daily to affected areas for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17323714','lexi-content-ref-Weston.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17323714','lexi-content-ref-Weston.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Moderate to severe disease:</b> Triamcinolone 0.05% (ointment), 0.1% (ointment, cream), ~0.2 mg/spray (aerosol spray), or 0.5% (ointment, cream): Topical: Apply once or twice daily to affected areas for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11134919','lexi-content-ref-Weston.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11134919','lexi-content-ref-Weston.1'])">Ref</a></span>); in patients with improvement, maintenance therapy is suggested with an intermittent application once daily for 2 consecutive days per week (eg, weekends) or 2 to 3 times per week to previously affected areas for up to 16 weeks. <b>Note:</b> For areas affecting the face, groin, or other areas with skin folds, lower-potency preparations are generally recommended (unless limited to short-term use [5 to 7 days] and then switched to lower potency) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24813302','lexi-content-ref-Weston.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24813302','lexi-content-ref-Weston.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Topical corticosteroids are generally well tolerated when used appropriately. Treatment courses of ~2 weeks are common for certain chronic skin conditions; however, longer or repeated intermittent courses can be appropriate, particularly when prescribed under the guidance of a dermatologist. Conversely, a shorter course may be sufficient depending upon response and when used for minor self-limiting skin conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53699f0d-af5c-4144-82af-9602f2da83cf">Contact dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contact dermatitis: Note: </b>If condition does not show prompt improvement (eg, within 1 to 2 weeks), reassess diagnosis and choice of treatment; consider evaluation by an experienced specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17039663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17039663'])">Ref</a></span>). In the management of corticosteroid-responsive dermatoses, lower-potency agents are often preferred for sites at increased risk for corticosteroid-induced skin atrophy (eg, face, intertriginous areas). However, use of higher-potency agents in these areas can be appropriate for certain indications when prescribed under the guidance of a dermatologist. See "Note" at the top of the "Dosing: Adult" field for potency guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Allergic contact dermatitis (localized), mild to moderate:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Face and/or flexural areas:</i> Triamcinolone: 0.025% (cream, lotion, ointment), 0.05% (ointment), 0.1% (cream, lotion, ointment): Topical: Apply once or twice daily to affected areas for 1 to 2 weeks; thereafter, may consider tapering (eg, with every other day application) over the subsequent 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brod.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brod.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hands, feet, or nonflexural areas:</i> Triamcinolone 0.5% (cream, ointment): Topical: Apply once or twice daily to affected areas for 2 to 4 weeks, or until resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brod.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brod.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Irritant contact dermatitis (localized), mild to moderate, acute or chronic: Note: </b>In general, ointments are the preferred vehicle.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Face and/or flexural areas: </i>Triamcinolone 0.025% (cream, lotion, ointment) or 0.1% (lotion): Topical: Apply once or twice daily to affected areas for 1 to 2 weeks; thereafter, may consider tapering (eg, with every other day application) over the subsequent 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brod.1','lexi-content-ref-Fransway.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brod.1','lexi-content-ref-Fransway.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nonfacial and/or nonflexural areas:</i> Triamcinolone 0.5% (cream, ointment): Topical: Apply once or twice daily to affected areas for 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brod.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brod.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Topical corticosteroids are generally well tolerated when used appropriately. Treatment courses of ~2 weeks are common for certain chronic skin conditions; however, longer or repeated intermittent courses can be appropriate, particularly when prescribed under the guidance of a dermatologist. Conversely, a shorter course may be sufficient depending upon response and when used for minor self-limiting skin conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab636031-c587-4b72-9839-247ad6d72495">Genital pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Genital pruritus (due to dermatitis) (adjunct): Note: </b>Use with conservative measures (eg, keeping area clean and dry, removal of offending agents). An evaluation for the underlying cause is essential as the etiology may be due to an infectious, neoplastic, systemic, or other process requiring definitive management.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Vulvar dermatitis, mild:</b> Triamcinolone 0.025% (cream, ointment, lotion), 0.05% (ointment), or 0.1% (cream, ointment, lotion): Topical: Apply to affected area once or twice daily for 2 to 4 weeks; therapy can be continued indefinitely at the minimum frequency for effective control of pruritus (goal &lt;14 days per month). Ointments are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Johnson.1','lexi-content-ref-29929595','lexi-content-ref-35411963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Johnson.1','lexi-content-ref-29929595','lexi-content-ref-35411963'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e9e06c-231a-4713-b1ec-aef706114647">Psoriasis, plaque</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis, plaque (limited disease):</b>
<b>Note:</b> In the management of corticosteroid-responsive dermatoses, lower-potency agents are often preferred for sites at increased risk for corticosteroid-induced skin atrophy (eg, face, intertriginous areas). However, use of higher-potency agents in these areas can be appropriate for certain indications when prescribed under the guidance of a dermatologist. See "Note" at the top of the "Dosing: Adult" field for potency guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Face and/or intertriginous areas:</i> Triamcinolone 0.025% (cream, lotion): Topical: Apply twice daily until lesions resolve; a common treatment course is 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.1','lexi-content-ref-23413913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.1','lexi-content-ref-23413913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Duration of therapy:</b> Topical corticosteroids are generally well tolerated when used appropriately. Treatment courses of ~2 weeks are common for certain chronic skin conditions; however, longer or repeated intermittent courses can be appropriate, particularly when prescribed under the guidance of a dermatologist. Conversely, a shorter course may be sufficient depending upon response and when used for minor self-limiting skin conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66302c89-8cc8-49f7-a54e-522f64125112">Seborrheic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seborrheic dermatitis:</b>
<b>Note:</b> Administer alone or in combination with a topical antifungal. In the management of corticosteroid-responsive dermatoses, lower-potency agents are often preferred for sites at increased risk for corticosteroid-induced skin atrophy (eg, face, intertriginous areas). However, use of higher-potency agents in these areas can be appropriate for certain indications when prescribed under the guidance of a dermatologist. See "Note" at the top of the "Dosing: Adult" field for potency guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Face, trunk, and/or intertriginous areas: </i> Triamcinolone 0.025% (cream, lotion): Topical: Apply once or twice daily until symptoms subside (usually 1 to 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sasseville.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sasseville.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chest or upper back:</i> Triamcinolone 0.05% (ointment), 0.1% (cream, ointment), or ~0.2 mg/spray (aerosol spray): Topical: Apply once or twice daily until symptoms subside (usually 1 to 2 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sasseville.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sasseville.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Duration of therapy:</b> Topical corticosteroids are generally well tolerated when used appropriately. Treatment courses of ~2 weeks are common for certain chronic skin conditions; however, longer or repeated intermittent courses can be appropriate, particularly when prescribed under the guidance of a dermatologist. Conversely, a shorter course may be sufficient depending upon response and when used for minor self-limiting skin conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b90d6923-f6ad-4590-8e65-45f5acbeb098">Stasis dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stasis dermatitis (off-label use): Note: </b>In the management of corticosteroid-responsive dermatoses, lower-potency agents are often preferred for sites at increased risk for corticosteroid-induced skin atrophy (eg, face, intertriginous areas). However, use of higher-potency agents in these areas can be appropriate for certain indications when prescribed under the guidance of a dermatologist. See "Note" at the top of the "Dosing: Adult" field for potency guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">Triamcinolone 0.1% (ointment) or 0.5% (ointment): Topical: Apply once or twice daily for 1 to 2 weeks; due to risk of skin atrophy and ulceration, avoid prolonged use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fransway.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fransway.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Duration of therapy:</b> Topical corticosteroids are generally well tolerated when used appropriately. Treatment courses of ~2 weeks are common for certain chronic skin conditions; however, longer or repeated intermittent courses can be appropriate, particularly when prescribed under the guidance of a dermatologist. Conversely, a shorter course may be sufficient depending upon response and when used for minor self-limiting skin conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8632081','lexi-content-ref-Goldstein.1','lexi-content-ref-20027937'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990335"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987688"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F9606708"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Use the lowest effective dose.</p></div>
<div class="block dop drugH1Div" id="F45650217"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16062" href="/d/html/16062.html" rel="external">see "Triamcinolone (topical): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosage should be based on severity of disease and patient response; use smallest amount for shortest period of time to avoid HPA axis suppression. Therapy should be discontinued when control is achieved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="db00c349-e8c7-4629-a65f-c9656671bb40">Dermatoses</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatoses (corticosteroid-responsive, including contact/atopic dermatitis):</b> Infants, Children, and Adolescents: Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, Ointment:</p>
<p style="text-indent:-2em;margin-left:6em;">0.025% or 0.05%: Apply thin film to affected areas 2 to 4 times daily</p>
<p style="text-indent:-2em;margin-left:6em;">0.1% or 0.5%: Apply thin film to affected areas 2 to 3 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion: 0.025% or 0.1%: Apply 3 to 4 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">Spray: Apply to affected area up to 3 to 4 times daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193005"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193006"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9606580"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for topical triamcinolone.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption, allergic contact dermatitis, atrophic striae, desquamation, folliculitis, hypertrichosis, hypopigmentation, local dryness, maceration of the skin, miliaria, perioral dermatitis, skin atrophy, skin blister</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Cushing syndrome, glycosuria, HPA-axis suppression, hyperglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral mucosa changes (paste; atrophy or maceration)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Secondary infection</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site burning, application site irritation, application site pruritus</p></div>
<div class="block coi drugH1Div" id="F9606550"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to triamcinolone or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Oral topical formulations only: Fungal, viral, or bacterial infections of the mouth or throat</p></div>
<div class="block war drugH1Div" id="F9606551"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Aerosol solution: Do not apply to underarms or groin unless directed by a health care professional; if improvement is not seen within 2 weeks, contact prescriber. Product is flammable; avoid heat, smoking, or flames when applying.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only; avoid contact with eyes. Do not use occlusive dressings on weeping or exudative lesions and general caution with occlusive dressings should be observed; discontinue if skin irritation or contact dermatitis should occur; do not use in patients with decreased skin circulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• High-potency products: Avoid the use of high-potency steroids on the face.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral cavity application: Do not apply paste to skin or eyes. When used as a topical agent in the oral cavity, if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878762"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress. Infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F9606835"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kenalog: 0.147 mg/g (63 g, 100 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.147 mg/g (63 g, 100 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triderm: 0.1% (28.4 g [DSC]); 0.5% (454 g) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025% (15 g, 80 g, 454 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025% (60 mL); 0.1% (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trianex: 0.05% (430 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tritocin: 0.05% (430 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.025% (15 g, 80 g, 454 g); 0.05% (110 g, 430 g); 0.1% (15 g, 30 g, 80 g, 453.6 g, 454 g); 0.5% (15 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Paste, Mouth/Throat, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kourzeq: 0.1% (5 g) [vanilla flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oralone: 0.1% (5 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Therapy Pack, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sila III: 0.1% (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triasil: 0.1% (1 ea)</p></div>
<div class="block geq drugH1Div" id="F9606542"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F9606837"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Kenalog External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.147 mg/g (per gram): $10.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Triamcinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.147 mg/g (per gram): $3.89 - $9.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Triamcinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $0.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $0.24 - $0.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $0.67 - $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Triderm External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $1.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Triamcinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per mL): $0.63 - $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per mL): $0.71 - $1.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Triamcinolone Acetonide External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.025% (per gram): $0.13 - $0.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $1.56 - $2.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $0.37 - $0.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per gram): $0.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Paste</b> (Kourzeq Mouth/Throat)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $15.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Paste</b> (Oralone Mouth/Throat)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $17.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Paste</b> (Triamcinolone Acetonide Mouth/Throat)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $16.12 - $16.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Therapy Pack</b> (Triasil External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per each): $3,610.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870639"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aristocort C: 0.5% (15 g, 50 g) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aristocort R: 0.1% (15 g, 30 g, 500 g) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triaderm: 0.025% ([DSC]); 0.1% (15 g, 500 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aristocort R: 0.1% (30 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triaderm: 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Paste, Mouth/Throat, as acetonide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oracort: 0.1% (7.5 g)</p></div>
<div class="block adm drugH1Div" id="F9606749"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral/dental paste: Do not apply paste to skin or eyes. Apply small amount into oral cavity until thin, smooth film develops; do not rub in; spreading the paste may result in a granular, gritty sensation and crumbling; apply at bedtime to allow contact of the medication with the lesion overnight; if more frequent application is necessary, apply after meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Topical products: In general, for optimal absorption, apply topical corticosteroids to moist skin immediately after bathing or after wet soaks. Occlusive dressings will also enhance drug absorption, often by a factor of 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldstein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldstein.1'])">Ref</a></span>). Occlusive dressing may be used if instructed by a health care professional.</p>
<p style="text-indent:-2em;margin-left:4em;">Aerosol spray: For external use only. Avoid heat, flame, or smoking when using. Avoid eyes and do not inhale if spraying near face. Container may be used upright or inverted. When using the spray button, spray at a distance of 3 to 6 inches from affected area. For hard-to-reach areas, insert the spray tube applicator into spray button and twist to seat. Point tube end away from body and face. Ensure the tube applicator is clean prior to use and wash after use. Move spray tube while applying, touching the surface of the affected area.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, ointment, lotion: For external use only; avoid contact with eyes.</p></div>
<div class="block admp drugH1Div" id="F52614420"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Dermal application: For external use only. Do not use on open skin; avoid contact with eyes; wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, ointment: Apply a thin film sparingly. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions. If an infection develops, discontinue use of occlusive dressings.</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Apply topical sparingly to affected areas as a thin film. May be used with occlusive dressings for management of psoriasis or recalcitrant conditions. If an infection develops, discontinue use of occlusive dressings.</p>
<p style="text-indent:-2em;margin-left:2em;">Spray: Avoid heat, flame, or smoking when using. Do not inhale if spraying near face. Container may be used upright or inverted. When using the spray button, spray at a distance of 3 to 6 inches from affected area. For hard to reach areas, insert the spray tube applicator into spray button and twist to seat. Point tube away from body and face. Be sure the tube applicator is clean prior to use and wash after use. Move spray tube while applying, touching the surface of the affected area. Do not use tight fitting diapers or plastic pants on a patient being treated in the diaper area, as this constitutes an occlusive dressing. Occlusive dressing may be used if instructed by a health care professional; monitor for infection.</p></div>
<div class="block use drugH1Div" id="F9606543"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aphthous stomatitis:</b> Oral/dental paste: Adjunctive treatment and temporary relief of symptoms associated with oral inflammatory and ulcerative lesions resulting from trauma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Corticosteroid-responsive dermatoses (eg, atopic dermatitis, contact dermatitis, vulvar dermatitis, psoriasis, seborrheic dermatitis):</b> Topical: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p></div>
<div class="block off-label drugH1Div" id="F53404681"><span class="drugH1">Use: Off-Label: Adult</span><p>Stasis dermatitis</p></div>
<div class="block mst drugH1Div" id="F9606493"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kenalog may be confused with Ketalar</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Medium, high, and very high potency topical corticosteroids, when used in neonates and infants &lt;1 year of age for diaper dermatitis, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of adrenal suppression; systemic absorption is higher in pediatric patients than adults (strong recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300168"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9606610"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Triamcinolone (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Topical).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56152250"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids may be used for the treatment of corticosteroid-responsive dermatosis, such as atopic dermatitis in patients planning a pregnancy (Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F9887155"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes; however, there may be an increased risk of low birth-weight infants following maternal use of potent or very potent topical products, especially in high doses, although this risk is likely to be low (Andersson 2021; Chi 2015; Chi 2017).</p>
<p style="text-indent:0em;margin-top:2em;">When first-line treatments, such as emollients, are insufficient, topical corticosteroids may be used for the treatment of atopic dermatitis in pregnant patients (Vestergaard 2019). Topical corticosteroids are classified by potency; the medication and formulation (eg, cream, gel, and/or salt form) contribute to the potency classification (Oakley 2021; Stacey 2021; Tadicherla 2009). In general, use of the least potent product in limited amounts is recommended during pregnancy. Mild to moderate potency corticosteroids are preferred; potent to very potent topical corticosteroids should only be used as alternative therapy in limited amounts under obstetrical care. Pregnant patients should avoid application of topical corticosteroids to areas with high percutaneous absorption (eg, armpit, skin folds, vulva) (Chi 2017) and caution should be used when applying to areas prone to striae formation (eg, abdomen, breast, thighs) (Vestergaard 2019).</p></div>
<div class="block brc drugH1Div" id="F9887157"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sufficient quantities of triamcinolone are absorbed following topical administration to produce detectable amounts in breast milk; however, systemic corticosteroids are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends that caution be used, topical corticosteroids are generally considered acceptable for use in patients who are breastfeeding (Butler 2014; WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid application of topical corticosteroids to the nipple and areola area until breastfeeding ceases; hypertension was noted in a breastfed infant when a high-potency topical corticosteroid was applied to the nipple (AAD-NPF [Elmets 2021]; Butler 2014; Leachman 2006). If needed, apply topical corticosteroids immediately after breastfeeding then clean nipples prior to the next feeding (Vestergaard 2019).</p></div>
<div class="block mop drugH1Div" id="F45650220"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Skin atrophy; HPA axis suppression. When used in the oral cavity (topical paste), if significant regeneration or repair of oral tissues has not occurred in seven days, re-evaluation of the etiology of the oral lesion is advised.</p></div>
<div class="block pha drugH1Div" id="F9606655"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Triamcinolone has intermediate to high range potency (dosage-form dependent).</p></div>
<div class="block phk drugH1Div" id="F9606657"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, and the use of occlusive dressings.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Biologic: 18 to 36 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (40%); feces (60%, some via biliary excretion)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962009"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Kenalog in orabase | Ledercort</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fortcinolona | Glytop | Glytop-f | Kenacort a | Ledercort | Ledercort d | Triamciterap | Triampoen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Volon a</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aristocort | Kenacort | Kenalog in orabase | Tricortone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aristocort | Cenolon | Cortefin | Kenacort a | Skinaderm | Stelone | Trialon | Zemalog</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Delphi | Kenacort</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Tess</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Polcortolon</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetonida de triancinolona | Acetonido de triancinolona | Coliaft | Colujet | Mud oral | Omcilon a orabase | Oncicrem A | Oncileg A | Oralsept | Theracort | Triancinolona acetonida</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Kenacort-a | Nasacort</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Tess</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kenacort-a</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bi nuo | Kenacort-a | Kenalog | Triamcinolone | Xing rui ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ledercort d</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Kenalog orabase | Triamcinolon | Triamcinolon hbf</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arutrin | Delphicort | Kortikoid | Linola triam | Linolacort triam | Tri-anemul | Triam | Triamcinolon | Triamcinolon Wolff | TriamCreme Lichtenstein | Triamgalen | Volon a | Volonimat | Volonimat N</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ftorocort | Kenalog | Polcortolon | Triamgalen | Volon a</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Topicort</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Kenalog orabase</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Kenacort t | Ledercort | Ledercort acetonid | Tricort</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Ledercort</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ahbina | Aristocort a | Delesil orabase | Dermacort | Euralog | Flexone | Kenacort a | Kenalog in orabase | Mecol orabase | Oracort | Oramedy | Orrepaste | Portasie orabase | Tess | Tramsone | Triaderm | Triamcinolone | Tricin | Trinoman | U triamcinolone | Yecolon orabase</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ftorocort</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Kenalog in orabase | Ketricin orabase | Oralog | Sinocort | Triamcort a | Tridez | Trilac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adcortyl | Adcortyl in orabase</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Kenalog | Kenalog orabase | Oracort</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Caziq | Cinort | Comcort | Cortrima | Excort | Kenacort | Ledercort | Orapaste | Orastik | Oraways | Orotim | Praiscort | Rapicort | Tess | Triamacort | Triora | Turbocort</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Ledercort</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Kenacin a | Kenalog orabase</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Coupe a | Coupe a fukuchi | Kenacort a | Kenalog | Ledercort | Ledercort alfresa | Muncorton | Nogiron | Ortexer | Rineton | Trianopollon yamakawa | Tricinolon</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Kemzid | Tess</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ahbina | Amcilone | Ariscort | Gemicort | Hanshin atoderm | Kenalog in orabase | Mas one q | Masclean | Mediderm | Oraderm | Oramedy | Sinskin | Steramin | Tial | Tiroue | Triamcinolone | Tricinol | Tricort | Trina</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Kenalog orabase | Ledercort</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ftorocort | Polcorton | Triamcinolon</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Delphi | Kenacort</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ftorocort | Kenalog orabase | Polcortolon | Senciderm | Triamcinolon | Triamcinolone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Azucort | Kenalog</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dermacort | Kanolone | Kenacort-a | Kenaderm | Kenalog in orabase | Keno oral | Oralon | Orrepaste | Tramsone | Triamcinolone | Tricilon | Trinlog | Trinolone | Tromecort</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Triton</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Delphi | Kenacort a | Triamcinolon | Triamcinolon vaselinecreme dmb fna | Triamcinolonacetonide | Triamcinolonacetonide aurobindo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Kenacort t | Volon a</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aristocort | Kenacort-a | Kenalog in orabase | Oracort</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cortiflex | Kenacort a | Kenacort e | Kenaderm-l | Kenaflam | Kenafrent | Triamcinolona | Triamcinolona medifarma | Triamcort</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Kenacort-a | Tricort</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Kenalog | Ledercort | Nasacort aq | Nasarin | Oralone | Triton</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Delphi | Delphicort | Polcortolon | Triamcinolon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aristocort | Aristocort a | Dermasorb ta | Kenalog | Kenalog in orabase | Oralone | Pediaderm ta | Sila iii | Silalite pak | Silazone ii | Triacet | Triamcinolone | Trianex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Psor meyco</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kenacort | Kenacort-A | Kenalog in Orabase | Kortilon-A</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cinacort | Fluorocort | Ftoderm | Ftorocort | Kenalog | Polcortolon | Triacort | Triamcinolon | Tricort</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Kenalog in orabase | Ledercort</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Kenacort t | Ledercort acetonid</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dermacort | Kenalog in orabase | Keno | Oral-t | Orrepaste | Tramsone | Triamcinolone | Trinolone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kenalog</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Triamcinolon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actyl | Aristocort | Aristocort a | B.p.cort | Bacera | Betgi cort | Betjicort | Centocort | Cinocort | Cinolone | Curran | Dermate | Dynacort | Facort | Ftorocort | Furama | Generlog | Kanolone | Kela | Kelamild | Kemzid | Kenacort-a | Kenalog in orabase | Kenalone | Keno | Kenolone | Lala | Laver | Lenicort | M-divate | Manolone | Metoral | Milanolone | Musaral | Oracort | Oracortia | Oral-t | Oralog | Orcilone | Orina | Orrepaste | Paloc | Pharmalog | Pharnolone | Q-ta | Risto | Sanocort | Sanocort A | Simacort | Skinolone | Starcort | Starlog | T Man Triamcinolone | T-cinolan | T-nolone | T-orapaste | T.a. | T.a. cream | T.a. lone | T.v.lone | Tacinol | Tony | Topilone | Tram | Tramsilone | Tri-am | Triam | Triam star | Triama | Triamcinolone | Trilosil | Trim | Trimasone | Trinoderm | Trinolone | Trinoman | Triseroid | Ulcerid | Vacinolone-v | Viomint | Votif | Zyno</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a orabase | Kortilon A Orabase</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amcicort | Ayco | Cinolone | Corkelin | Cortibond orabase | Encort | Euderma | Gentlecort | Gentlecort hp | Kenacort-a | Kenalog | Kingtrilone | Kosuler | Lecortin | Ledercort | Ledercort a | Licolin | Mecol orabase | Oralog | Rucos | Scoro | Scort | Seu su | Sfusone | Shinolon | Shu Kou Yan | Stacort | Sunbin | Suyenin | Tracort | Trancine | Trialon | Triamcine | Triamcinolone | Triamcinolone in orabase "golden horse" | Veimincort | Weilisin In Orabase | Yecolon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Focort Darnitsa | Ftorocort | Polcortolon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Rezamid d | Rezamid f | Rezamid m</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kenacort a | Ledercorde</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amtanolon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kenalog | Ledercort d</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Orrepaste</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25346356">
<a name="25346356"></a>Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers. <i>Dtsch Arztebl Int</i>. 2014;111(40):665-673. doi: 10.3238/arztebl.2014.0665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/25346356/pubmed" id="25346356" target="_blank">25346356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17039663">
<a name="17039663"></a>American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology. Contact dermatitis: a practice parameter [published correction appears in <i>Ann Allergy Asthma Immunol</i>. 2006;97(6):819]. <i>Ann Allergy Asthma Immunol</i>. 2006;97(3)(suppl 2):S1-S38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/17039663/pubmed" id="17039663" target="_blank">17039663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33950165">
<a name="33950165"></a>Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight. <i>JAMA Dermatol</i>. 2021. doi:10.1001/jamadermatol.2021.1090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/33950165/pubmed" id="33950165" target="_blank">33950165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brod.1">
<a name="Brod.1"></a>Brod BA. Management of allergic contact dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17323714">
<a name="17323714"></a>Buys LM. Treatment options for atopic dermatitis. <i>Am Fam Physician</i>. 2007;75(4):523-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/17323714/pubmed" id="17323714" target="_blank">17323714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28233354">
<a name="28233354"></a>Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(5):761-773. doi:10.1111/jdv.14101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/28233354/pubmed" id="28233354" target="_blank">28233354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26497573">
<a name="26497573"></a>Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. <i>Cochrane Database Syst Rev</i>. 2015;(10):CD007346. doi:10.1002/14651858.CD007346.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/26497573/pubmed" id="26497573" target="_blank">26497573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dermasorb.1">
<a name="Dermasorb.1"></a>Dermasorb TA (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories, Inc.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8632081">
<a name="8632081"></a>Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. <i>J Am Acad Dermatol</i>. 1996;34(5, pt 1):824-829.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/8632081/pubmed" id="8632081" target="_blank">8632081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24813302">
<a name="24813302"></a>Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. <i>J Am Acad Dermatol</i>. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/24813302/pubmed" id="24813302" target="_blank">24813302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.1">
<a name="Feldman.1"></a>Feldman SR. Treatment of psoriasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fransway.1">
<a name="Fransway.1"></a>Fransway AF and Fowler J. Irritant contact dermatitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fransway.2019">
<a name="Fransway.2019"></a>Fransway AF. Stasis dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldstein.1">
<a name="Goldstein.1"></a>Goldstein BG, Goldstein AO. General principles of dermatologic therapy and topical corticosteroid use. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11134919">
<a name="11134919"></a>Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. <i>Health Technol Assess</i>. 2000;4(37):1-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/11134919/pubmed" id="11134919" target="_blank">11134919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Johnson.1">
<a name="Johnson.1"></a>Johnson NR, Scheinman PL, Watson AJ. Vulvar dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kenalog.1">
<a name="Kenalog.1"></a>Kenalog spray (triamcinolone acetonide) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kourzeq.1">
<a name="Kourzeq.1"></a>Kourzeq (triamcinolone) [prescribing information]. Oak Park, IL: MidAmerica Pharmaceuticals LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18079551">
<a name="18079551"></a>Lewis-Jones S, Mugglestone MA, Guideline Development Group. Management of atopic eczema in children aged up to 12 years: summary of NICE guidance. <i>BMJ</i>. 2007;335(7632):1263-1264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/18079551/pubmed" id="18079551" target="_blank">18079551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10905785">
<a name="10905785"></a>McBride DR. Management of aphthous ulcers. <i>Am Fam Physician</i>. 2000;62(1):149-154, 160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/10905785/pubmed" id="10905785" target="_blank">10905785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33108015">
<a name="33108015"></a>Oakley R, Arents BWM, Lawton S, Danby S, Surber C. Topical corticosteroid vehicle composition and implications for clinical practice. <i>Clin Exp Dermatol</i>. 2021;46(2):259-269. doi:10.1111/ced.14473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/33108015/pubmed" id="33108015" target="_blank">33108015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23413913">
<a name="23413913"></a>Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. <i>Br J Dermatol</i>. 2013;168(5):954-967. doi: 10.1111/bjd.12276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/23413913/pubmed" id="23413913" target="_blank">23413913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sasseville.1">
<a name="Sasseville.1"></a>Sasseville D. Seborrheic dermatitis in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29929595">
<a name="29929595"></a>Savas JA, Pichardo RO. Female genital itch. <i>Dermatol Clin</i>. 2018;36(3):225-243. doi: 10.1016/j.det.2018.02.006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/29929595/pubmed" id="29929595" target="_blank">29929595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33719380">
<a name="33719380"></a>Stacey SK, McEleney M. Topical corticosteroids: choice and application. <i>Am Fam Physician.</i> 2021;103(6):337-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/33719380/pubmed" id="33719380" target="_blank">33719380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20027937">
<a name="20027937"></a>Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. <i>J Drugs Dermatol</i>. 2009;8(12):1093-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/20027937/pubmed" id="20027937" target="_blank">20027937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25254615">
<a name="25254615"></a>Taylor J, Glenny AM, Walsh T, et al. Interventions for the management of oral ulcers in Behçet's disease. <i>Cochrane Database Syst Rev</i>. 2014;(9):CD011018. doi: 10.1002/14651858.CD011018.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/25254615/pubmed" id="25254615" target="_blank">25254615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GW.1">
<a name="GW.1"></a>Triamcinolone acetonide cream [prescribing information]. South Plainfield, NJ: G&amp;W Laboratories, Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taro.1">
<a name="Taro.1"></a>Triamcinolone acetonide dental paste [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals USA Inc; August 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quagen.1">
<a name="Quagen.1"></a>Triamcinolone acetonide lotion [prescribing information]. West Caldwell, NJ: Quagen Pharmaceuticals LLC; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VersaPharm.1">
<a name="VersaPharm.1"></a>Triamcinolone acetonide lotion [prescribing information]. Marietta, GA: VersaPharm Incorporated; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Macleods.1">
<a name="Macleods.1"></a>Triamcinolone acetonide ointment [prescribing information]. Plainsboro, NJ: Macleods Pharma USA, Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trianex.1">
<a name="Trianex.1"></a>Trianex (triamcinolone) [prescribing information]. Farmville, NC: CMP Pharma, Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Triderm.1">
<a name="Triderm.1"></a>Triderm (triamcinolone acetonide) [prescribing information]. Johnson City, TN: Crown Laboratories; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tritocin.1">
<a name="Tritocin.1"></a>Tritocin (triamcinolone acetonide) [prescribing information]. Wilmington, DE: Eckson Labs; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35411963">
<a name="35411963"></a>van der Meijden WI, Boffa MJ, Ter Harmsel B, et al. 2021 European guideline for the management of vulval conditions. <i>J Eur Acad Dermatol Venereol.</i> 2022;36(7):952-972. doi:10.1111/jdv.18102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/35411963/pubmed" id="35411963" target="_blank">35411963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol</i>. 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/triamcinolone-topical-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weston.1">
<a name="Weston.1"></a>Weston WL, Howe W. Treatment of atopic dermatitis (eczema). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 9964 Version 548.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
